The anniversary celebration for the line-smoothing, migraine-relieving medication is expected to last a year.
Endo gets a new president, Allergan settles a Botox case
An April 25 JAMA article said Botox does nothing for episodic migraine patients. Allergan brushed off the critique.
US District Court Judge Andrew Guilford slammed the breaks on Merz's foray into a market dominated by Botox, siding with Allergan in a case about stealing intellectual property and poaching sales reps.
Allergan removed some doctor-payment records from its website that the drugmaker had posted from 2010-2011 as a result of a Botox legal settlement.
Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.